Pyxis Oncology Catalysts on Track With Upcoming Trial Results in Head, Neck Cancer Treatment, RBC Says
RBC Capital Maintains Outperform on Pyxis Oncology, Raises Price Target to $7
Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
Pyxis Oncology Q3 EPS $(0.24) Beats $(0.29) Estimate
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Pyxis Oncology To Present Late-Breaking Oral Data On MICVO Monotherapy In Previously Treated Recurrent/Metastatic Head And Neck Cancer At EORTC-NCI-AACR Symposium
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Pyxis Oncology stock falls on public offering announcement
Pyxis Oncology Announces Proposed Public Offering
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed
Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma - Slideshow
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology shares fall 7% despite updated MICVO trial results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.